ROSENWALD LINDSAY A MD 4

What Happened

• Lindsay A. Rosenwald, MD, a director of Journey Medical Corp (DERM), was granted 10,000 restricted stock units (RSUs) on June 25, 2026. The grant is reported as an acquisition at $0.00 per share (total cash consideration $0). The RSUs vest in full on June 25, 2027.

Key Details

• Transaction date: 2026-06-25; Form 4 filed: 2026-06-26 (timely filing).
• Grant: 10,000 RSUs recorded as acquisition at $0.00 per share (no cash exchanged).
• Vesting: 10,000 shares vest on June 25, 2027 (per footnote F1).
• Footnotes: F2 notes other RSUs held by the reporting person vest over various periods; F3 indicates shares are held by an LLC over which Dr. Rosenwald, as managing member, is deemed to have voting and investment power.
• Shares owned after transaction: not specified in the provided excerpt of the filing.

Context

• RSUs are an award that convert into actual shares only when they vest; this grant does not represent an immediate sale or purchase in the open market. Such awards are commonly used for retention or long-term incentive purposes and do not by themselves indicate a change in insider sentiment.